Physalis alkekengi and Alhagi maurorum ameliorate the side effect of cisplatin-induced nephrotoxicity

Cancer Gene Therapy

Volumn 23, Issue 7, 2016, Pages 235-240

  Changizi Ashtiyani, S ^a   Alizadeh, M ^a   Najafi, H ^b   Babaei, S ^a   Khazaei, M ^a   Jafari, M ^a   Hossaini, N ^c   Avan, A ^d   Bastani, B ^e  

^a ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ARAK UNIVERSITY   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALHAGI MAURORUM EXTRACT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CISPLATIN; CREATININE; MALONALDEHYDE; NITROGEN; PHYSALIS ALKEKENGI EXTRACT; PLANT EXTRACT; UNCLASSIFIED DRUG; UREA; ANTINEOPLASTIC AGENT;

ALHAGI MAURORUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG POTENCY; FABALES; HISTOPATHOLOGY; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PHYSALIS; PHYSALIS ALKEKENGI; PRACTICE GUIDELINE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; FABACEAE; KIDNEY FAILURE; KIDNEY PROXIMAL TUBULE; ORAL DRUG ADMINISTRATION; PATHOLOGY; PRECLINICAL STUDY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CISPLATIN; DRUG EVALUATION, PRECLINICAL; FABACEAE; KIDNEY TUBULES, PROXIMAL; MALE; OXIDATIVE STRESS; PHYSALIS; PLANT EXTRACTS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY;

EID: 84976322950     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2016.24     Document Type: Article

References (46)

1. Hartmann JT, Fels LM, Knop S, Stolt H, Kanz L, Bokemeyer C. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs. 2000; 18: 281-289.
2. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003; 4: 889-901.
3. Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity, and nephrotoxicity following high-dose cisplatin, and amifostine. Pediatr Hematol Oncol. 2005; 22: 441-445.
4. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003; 23: 460-464.
5. Boulikas T. Poly (ADP-ribose) synthesis in blocked, and damaged cells, and its relation to carcinogens. Anticancer Res. 1992; 12: 885-898.
6. Saad SY, Arafah MM, Najjar TA. Effects of mycophenolate mofetil on cisplatininduced renal dysfunction in rats. Cancer Chemother Pharmacol. 2007; 59: 455-460.
7. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin Nephrotoxicity. Toxins. 2010; 2: 2490-2518.
8. Kuhad A, Pilkhwal S, Sharma S, Tirkey N, Chopra K. Effect of curcumin on inflammation, and oxidative stress in cisplatin induced experimental nephrotoxicity. J Agric Food Chem. 2007; 12: 10150-10155.
9. Ramesh G, Reeves WB. TNF-R mediates chemokine, and cytokine expression, and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002; 110: 835-842.
10. Baek S, Kwon C, Kim J, Woo J, Jung J, Kim Y. Differential roles of hydrogen peroxides, and hydroxyl radical in cisplatin induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med. 2003; 142: 178-186.
11. Ge Y, Duan Y, Fang G, Zhang Y, Wang S. Study on biological activities of Physalis alkekengi var. francheti polysaccharide. J Sci Food Agric. 2009; 89: 1593-1598.
12. Hoshani M, Aghdasi M. Inhibition effects of Physalis alkekengi extract on xanthine oxidase activity in different phenological stages. Clin biochem. 2011; 8: 854.
13. Ji L, Yuan Y, Luo L, Chen Z, Ma X, Ma Z, et al. Physalins with anti-inflammatory activity are present in Physalis alkekengi var. franchetii, and can function as Michael reaction acceptors. Steroids. 2012; 77: 441-447.
14. Chedea VS, Pintea A, Bunea A, Braicu C, Stanila A, Socaciu C. Physalis alkekengi carotenoidic extract inhibitor of soybean lipoxygenase-1 activity. BioMed Research Int. 2014; 2014: 589168.
15. Kang H, Kwon SR, Choi HY. Inhibitory effect of Physalis alkekengi L. var. franchetii extract, and its chloroform fraction on LPS or LPS/IFN-?-stimulated inflammatory response in peritoneal macrophages. J Ethnopharmacology. 2011; 135: 95-101.
16. Ahmad S, Riaz N, Saleem M, Jabbar A, Nisar-Ur-Rehman, Ashraf M. Antioxidant flavonoids from Alhagi maurorum. J Asian Nat Prod Res 2010 Feb; 12: 138-143.
17. Awaad AS, El-meligy RM. Anti-inflammatory, antinociceptive, and antipyretic effects of some desert plants. J Saudi Chem Soc. 2011; 15: 367-373.
18. Laghari AH, Memon S, Nelofar A, Khan KM. Alhagi maurorum: a convenient source of lupeol. Industrial Crops Products. 2011; 34: 1141-1145.
19. Shaker E, Mahmoud H, Mnaa S. Anti-inflammatory, and anti-ulcer activity of the extract from Alhagi maurorum (camelthorn). Food Chem Toxicol. 2010; 48: 2785-2790.
20. Muhammad G, Hussain MA, Anwar F, Ashraf M, Gilani AH. Alhagi: a plant genus rich in bioactives for pharmaceuticals. Phytother Res. 2015; 29: 1-13.
21. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979; 95: 351-358.
22. Benzie IF, Strain JJ. Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids, and modified version for simultaneous measurement of total antioxidant power, and ascorbic acid concentration. Methods Enzymol. 1999; 299: 15-27.
23. Changizi Ashtiyani S, Najafi H, Jalalvandi S, Hosseinei F. Protective effects of Rosa canina L fruit extracts on renal disturbances induced by reperfusion injury in rats. Iran J Kidney Dis. 2013; 7: 290-298.
24. Najafi H, Firouzifar MR, Shafaat O, Changizi Ashtiyani S, Hosseini N. Protective effects of Tribulus terrestris L extract against acute kidney injury induced by reperfusion injury in rats. Iran J Kidney Dis. 2014; 8: 292-298.
25. Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ. Irreproducibility of the activity, and chronicity indices limits their utility in the management of lupus nephritis. Am J Kidney Dis. 1993; 21: 374-377.
26. Strenberg SS. Diagnostic Surgical Pathology, 3rd edn. Lippincott Williams & Wilkins, 1996, pp 1701-1785.
27. Sugiyama S. Adverse effects of antitumor drug cisplatin on rat kidney mitochondria: disturbances in glutathione peroxidase activity. Biochem Biophys Res Commun. 1989; 159: 1121-1127.
28. Daugaard C, Abildgaard U. Cisplatin nephrotoxicity. Cancer Chemother Pharmacol. 1989; 25: 1.
29. Somani SM, Husain K, Whitworth C, Trammel GL, Malafa M, Rybak LP. Dosedependent protection by lipoic acid against cisplatin induced nephrotoxicity in rats: antioxidant defense system. Pharmacol Toxicol. 2000; 86: 234-241.
30. Aydogan S, Yapislar H, Artis S, Aydogan B. Impaired erythrocytes deformability in H(2)O(2)-induced oxidative stress: protective effect of L-carnosine. Clin Hemorheol Microcirc. 2008; 39: 93-98.
31. Naziroglu M, Karaoglu A, Aksoy AO. Selenium, and high dose Vitamin E administration protects cisplatin-induced oxidative damage to renal, liver, and lens tissues in rats. Toxicol. 2004; 195: 221-230.
32. Saad SY, Al-Rikabi AC. Protection effects of taurine supplementation against cisplatin-induced nephrotoxicity in rats. Chemotherapy. 2002; 48: 42-48.
33. Borrego A, Zamora ZB, Gonzalez R, Romay C, Menendez S, Hernandez F, et al. Protection by ozone preconditioning is mediated by the antioxidant system in cisplatin-induced nephrotoxicity in rats. Mediators Inflamm. 2004; 13: 13-19.
34. Gonzalez R, Borrego A, Zamora Z, Romay C, Hernandez F, Menendez S, et al. Reversion by ozone treatment of acute nephrotoxicity induced by cisplatin in rats. Mediators Inflamm. 2004; 13: 307-312.
35. De Martinis BS, Bianchi MD. Effect of Vitamin C supplementation against cisplatininduced toxicity, and oxidative DNA damage in rats. Pharmacol Res. 2001; 44: 317-320.
36. Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol. 2001; 12: 2683-2690.
37. Srivastava R, Farookh A, Ahmad N, Misra M, Hasan S, Husain M. Evidence for involvement of nitric oxide in cisplatin induced toxicity in rats. Biometals. 1996; 9: 139-142.
38. Yildirim Z, Sogut S, Odaci E, Iraz M, Ozyurt H, Kotuk M, et al. Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacol Res. 2003; 47: 149-156.
39. Ozen S, Akyol O, Iraz M, Sogut S, Ozugurlu F, Ozyurt H, et al. Role of caffeic acid phenethyl ester, an active component of propolis, against cisplatin-induced nephrotoxicity in rats. J Appl Toxicol. 2004; 24: 27-35.
40. Mora Lde O, Antunes LM, Francescato HD, Bianchi Mde L. The effects of oral glutamine on cisplatin-induced nephrotoxicity in rats. Pharmacol Res. 2003; 47: 517-522.
41. Ludwig T, Riethmuller C, Gekle M, Schwerdt G, Oberleithner H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int. 2004; 66: 196-202.
42. Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota HJ, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005; 167: 1477-1484.
43. Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of cisplatin with the human organic cation transporter 2. Clin Cancer Res. 2008; 14: 3875-3880.
44. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast, and mammals. Proc Natl Acad Sci USA. 2002; 99: 14298-14302.
45. Laghari AH, Ali Memon A, Memon S, Nelofar A, Khan KM, Yasmin A. Determination of free phenolic acids, and antioxidant capacity of methanolic extracts obtained from leaves, and flowers of camel thorn (Alhagi maurorum). Nat Prod Res. 2012; 26: 173-176.
46. Laghari AH, Memon S, Nelofar A, Khan KM, Yasmin A, Syed MN, et al. A new flavanenol with urease-inhibition activity isolated from roots of manna plant camelthorn (Alhagi maurorum). J Mol Structure. 2010; 965: 65-67.